Provox 2® and Provox Vega® device life-time: a case-crossover study with multivariate analysis of possible influential factors and duration

Abstract

Results confirmed the non-significant differences on device life between Provox Vega and Provox 2, as well as the relevant role of radiotherapy treatment in the increase of replacements and diminution of the device duration.

Analysis of Factors Affecting the Longevity of Voice Prosthesis Following Total Laryngectomy with a Review of Literature

“…These data agree with the existing literature [2]. What's striking about the obtained results is the excellent mean device life-time (16 months), which is much higher than the one shown in the literature in general [3], as well as in the most recent articles [4,5] that place the cipher in 2-4 months. This is a fact that the authors themselves highlight in their own review.…”

Use of double flange voice prosthesis for periprosthetic leakage in laryngectomised patients: A prospective case‐crossover study

“…Comparing the most recent studies, authors reported that the median device life of the Provox Vega indwelling voice prosthesis is between 66 and 75 days. 3,4 The data found in our study do not differ in this sense. The most noteworthy of the results obtained is the mean lifetime achieved with the Provox XtraSeal, assuming an increase in more than two months without the need for replacement in patients with periprosthetic leakage compared to the Provox Vega, being the first work that studies and demonstrates this improvement.…”

“…[8][9][10] In previous studies comparing two different generations of Provox, it had been shown that radiotherapy significantly affected the survival of the VP, being to a greater extent the Provox 2 than the Provox Vega. 3 The analysis performed in this study curiously finds the opposite in this cohort of patients. There seems to These findings support the use of Provox XtraSeal in patients with increased prosthesis replacements due to periprosthetic leakage, order to reduce the number of changes and therefore increasing the survival of VP.…”

“…The most frequent reason for replacement in the study was endoprosthesis leakage, results that coincide with those obtained in previous reports. 3,4 Unlike these, the findings of this study are not exposed to biases because all the reasons for change were collected, as well as the prospective nature of the study. The second most frequent cause of replacement, and for which the placement of a Provox XtraSeal would be recommended, is the periprosthetic leak.…”

“…These results are also consistent with previous studies. 3,4 The influence of radiotherapy treatment has been widely studied over prosthetic device life and the onset of tracheoesophageal fistula-related pathologies, increasing the rigidity and decreasing the thickness of the tracheal wall, as well as increasing the diameter of the fistula. [8][9][10] In previous studies comparing two different generations of Provox, it had been shown that radiotherapy significantly affected the survival of the VP, being to a greater extent the Provox 2 than the Provox Vega.…”